{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T21:41:34Z","timestamp":1779140494820,"version":"3.51.4"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Vitiligo-like leucoderma is being increasingly reported in patients with breast cancer treated with cyclin-dependent kinase 4 and 6 (CDK4\/6) inhibitors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To systematically review the characteristics of CDK4\/6 inhibitor-induced vitiligo-like leucoderma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A comprehensive literature search was conducted to identify published cases of patients with vitiligo-like leucoderma following CDK4\/6 inhibitor therapy administered for advanced breast cancer. The cases of three additional patients from our tertiary vitiligo clinic are also reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirteen publications met the inclusion criteria, with a study population of 62 patients, including the 3 newly reported patients attending our vitiligo clinic. All patients were female; the median age was 61\u2005years (range 39\u201387\u2005years). Ribociclib was the CDK4\/6 inhibitor most frequently associated with vitiligo-like leucoderma in 76% of patients (47\/62). The condition predominantly affected sun-exposed areas (88%, 36\/41) and caused symptoms such as intense pruritus in 59% of patients (24\/41). Despite multiple treatment methods, 56% of the patients (34\/61) showed no repigmentation. CDK4\/6 inhibitor therapy was discontinued in 13 of 62 patients (21%) for various reasons, including vitiligo-like leucoderma; however, cessation did not improve the outcome. Most studies lacked data on progression-free survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>CDK4\/6-inhibitor-induced vitiligo-like leucoderma has distinct clinical characteristics compared with classic vitiligo and is mostly recalcitrant to treatment. Stopping CDK4\/6 inhibitors does not alleviate or improve the condition. Further research is essential to elucidate its prognostic significance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llaf123","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T04:40:59Z","timestamp":1741927259000},"page":"1598-1605","source":"Crossref","is-referenced-by-count":3,"title":["Vitiligo-like leucoderma following cyclin-dependent kinase 4 and 6 inhibitor treatment: systematic review of the literature"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5998-0621","authenticated-orcid":false,"given":"Maya","family":"Engler Markowitz","sequence":"first","affiliation":[{"name":"Division of Dermatology, Rabin Medical Center \u2013 Beilinson Hospital , Petach Tikva ,","place":["Israel"]},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen Annette","family":"Barak Levitt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Emek Medical Center , Afula ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rotem","family":"Merose","sequence":"additional","affiliation":[{"name":"Oncology Institute, Shamir Medical Center , Zerifin, Be'er Ya'akov ,","place":["Israel"]},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Didkovski","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Department of Pathology and Cytology, Rabin Medical Center \u2013 Beilinson Hospital , Petach Tikva ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Snast","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Rabin Medical Center \u2013 Beilinson Hospital , Petach Tikva ,","place":["Israel"]},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meital","family":"Oren-Shabtai","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Rabin Medical Center \u2013 Beilinson Hospital , Petach Tikva ,","place":["Israel"]},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aviv","family":"Barzilai","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Department of Dermatology, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]},{"name":"Institute of Pathology, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Mimouni","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Rabin Medical Center \u2013 Beilinson Hospital , Petach Tikva ,","place":["Israel"]},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2323-3512","authenticated-orcid":false,"given":"Shany","family":"Sherman","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Rabin Medical Center \u2013 Beilinson Hospital , Petach Tikva ,","place":["Israel"]},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"2025072412172156200_llaf123-B1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1159\/000506103","article-title":"Vitiligo: a review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"2025072412172156200_llaf123-B2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1034\/j.1600-0749.2003.00032.x","article-title":"Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families","volume":"16","author":"Alkhateeb","year":"2003","journal-title":"Pigment Cell Res"},{"key":"2025072412172156200_llaf123-B3","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00296-022-05247-5","article-title":"Anti-programmed death-1 inhibitor nivolumab-induced immune-related adverse events: hepatitis, renal insufficiency, myositis, vitiligo, and hypothyroidism: a case-based review","volume":"43","author":"Zeki\u0107","year":"2023","journal-title":"Rheumatol Int"},{"key":"2025072412172156200_llaf123-B4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2025072412172156200_llaf123-B5","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1186\/s12885-020-07508-7","article-title":"The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies","volume":"20","author":"Wu","year":"2020","journal-title":"BMC Cancer"},{"key":"2025072412172156200_llaf123-B6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/1346-8138.15345","article-title":"Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: a multi-institutional retrospective study","volume":"47","author":"Matsuya","year":"2020","journal-title":"J Dermatol"},{"key":"2025072412172156200_llaf123-B7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10549-020-05914-w","article-title":"Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors","volume":"185","author":"Sollena","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2025072412172156200_llaf123-B8","doi-asserted-by":"crossref","first-page":"1611115","DOI":"10.3389\/pore.2023.1611115","article-title":"Vitiligo-like lesions induced by cyclin-dependent kinase 4\/6 inhibitor Palbociclib: a case report and literature review","volume":"29","author":"Gao","year":"2023","journal-title":"Pathol Oncol Res"},{"key":"2025072412172156200_llaf123-B9","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/ajco.13585","article-title":"Drug induced vitiligo-like depigmentation from a CDK 4\/6 inhibitor","volume":"18","author":"Chan","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"key":"2025072412172156200_llaf123-B10","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2025072412172156200_llaf123-B11","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2025072412172156200_llaf123-B12","first-page":"e2022045","article-title":"Ribociclib-induced vitiligo: a case report","volume":"12","author":"Silvestre Torner","year":"2022","journal-title":"Dermatol Pract Concept"},{"key":"2025072412172156200_llaf123-B13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2147\/CCID.S344867","article-title":"Vitiligo-like lesions in a patient with metastatic breast cancer treated with cyclin-dependent kinase (CDK) 4\/6 inhibitor: a case report and literature review","volume":"15","author":"Sharaf","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2025072412172156200_llaf123-B14","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1111\/ijd.16356","article-title":"Vitiligo-like lesions induced by cyclin-dependent kinase 4\/6 inhibitor palbociclib","volume":"62","author":"Romagnuolo","year":"2023","journal-title":"Int J Dermatol"},{"key":"2025072412172156200_llaf123-B15","doi-asserted-by":"crossref","first-page":"e248782","DOI":"10.1136\/bcr-2022-248782","article-title":"Ribociclib-induced extensive vitiligo-like lesions: possible pathomechanisms with clinical, dermoscopic and histological correlation","volume":"15","author":"Anjaneyan","year":"2022","journal-title":"BMJ Case Rep"},{"key":"2025072412172156200_llaf123-B16","doi-asserted-by":"crossref","first-page":"1067264","DOI":"10.3389\/fonc.2023.1067264","article-title":"Case report: vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response","volume":"13","author":"Pasqualoni","year":"2023","journal-title":"Front Oncol"},{"key":"2025072412172156200_llaf123-B17","doi-asserted-by":"crossref","DOI":"10.1177\/10781552231156521","article-title":"Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer","author":"T\u00fcrkel","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"2025072412172156200_llaf123-B18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/ijp.ijp_85_23","article-title":"Photoallergic dermatitis and vitiligo-like lesion in a patient with metastatic breast cancer using ribociclib","volume":"55","author":"Mente\u015fo\u011flu","year":"2023","journal-title":"Indian J Pharmacol"},{"key":"2025072412172156200_llaf123-B19","doi-asserted-by":"crossref","first-page":"e12923","DOI":"10.1111\/phpp.12923","article-title":"Vitiligo-like depigmentation affecting sun-exposed areas caused by palbociclib","volume":"40","author":"P\u00e9rez","year":"2024","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2025072412172156200_llaf123-B20","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.3390\/cancers15143658","article-title":"Cyclin-dependent kinase 4\/6 inhibitors and dermatologic adverse events: results from the EADV Task Force \u201cDermatology for Cancer Patients\u201d international study","volume":"15","author":"Sollena","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025072412172156200_llaf123-B21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10549-023-07217-2","article-title":"Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors","volume":"204","author":"Bang","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"2025072412172156200_llaf123-B22","article-title":"FDA Adverse event reporting system (FAERS) database","author":"US Food and Drug Administration"},{"key":"2025072412172156200_llaf123-B23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12016-021-08868-z","article-title":"Clinical features, immunopathogenesis, and therapeutic strategies in vitiligo","volume":"61","author":"Wang","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025072412172156200_llaf123-B24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1346-8138.1994.tb01770.x","article-title":"Generalized vitiligo preceded by a generalized figurate erythematosquamous eruption","volume":"21","author":"Arata","year":"1994","journal-title":"J Dermatol"},{"key":"2025072412172156200_llaf123-B25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000018374","article-title":"A figurate papulosquamous variant of inflammatory vitiligo","volume":"200","author":"Lee","year":"2000","journal-title":"Dermatology"},{"key":"2025072412172156200_llaf123-B26","doi-asserted-by":"crossref","first-page":"e2022107","DOI":"10.5826\/dpc.1203a107","article-title":"Inflammatory vitiligo","volume":"12","author":"Chang","year":"2022","journal-title":"Dermatol Pract Concept"},{"key":"2025072412172156200_llaf123-B27","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1590\/abd1806-4841.20142717","article-title":"Vitiligo \u2013 Part 2 \u2013 classification, histopathology and treatment","volume":"89","author":"Faria","year":"2014","journal-title":"An Bras Dermatol"},{"key":"2025072412172156200_llaf123-B28","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jaad.2023.12.040","article-title":"Vitiligo","volume":"90","author":"Manoj","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025072412172156200_llaf123-B29","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jaad.2020.04.058","article-title":"Cutaneous adverse reactions to anti-PD-1 treatment \u2013 a systematic review","volume":"83","author":"Simonsen","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025072412172156200_llaf123-B30","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025072412172156200_llaf123-B31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025072412172156200_llaf123-B32","article-title":"2023 annual report on form 10-K","author":"Eli Lilly and Company"},{"key":"2025072412172156200_llaf123-B33","author":"Novartis"},{"key":"2025072412172156200_llaf123-B34","author":"Pfizer Inc"},{"key":"2025072412172156200_llaf123-B35","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamadermatol.2024.5136","article-title":"Immune checkpoint inhibitor-induced vitiligo-like depigmentation","volume":"161","author":"Starace","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2025072412172156200_llaf123-B36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/09546634.2020.1735615","article-title":"Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and meta-analysis","volume":"33","author":"Phan","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2025072412172156200_llaf123-B37","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/jamadermatol.2019.0696","article-title":"Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2025072412172156200_llaf123-B38","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/pcmr.12949","article-title":"An update on vitiligo pathogenesis","volume":"34","author":"Seneschal","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"2025072412172156200_llaf123-B39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","article-title":"New discoveries in the pathogenesis and classification of vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025072412172156200_llaf123-B40","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov"},{"key":"2025072412172156200_llaf123-B41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccell.2018.03.023","article-title":"CDK4\/6 inhibitors: the mechanism of action may not be as simple as once thought","volume":"34","author":"Klein","year":"2018","journal-title":"Cancer Cell"},{"key":"2025072412172156200_llaf123-B42","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.3390\/ijms24032236","article-title":"Deciphering the immunomodulatory role of cyclin-dependent kinase 4\/6 inhibitors to the tumor microenvironment","volume":"24","author":"Pandey","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025072412172156200_llaf123-B43","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.annonc.2024.07.243","article-title":"Autoimmune \u00adbullous diseases induced by cyclin-dependent kinase 4\/6 \u00adinhibitors \u2013 first cohort from the EADV task force \u201cDermatology for Cancer Patients\u201d","volume":"35","author":"Ortiz-Brugues","year":"2024","journal-title":"Ann Oncol"},{"key":"2025072412172156200_llaf123-B44","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40264-021-01071-1","article-title":"Emerging skin toxicities in patients with breast cancer treated with new cyclin-\u00addependent kinase 4\/6 inhibitors: a systematic review","volume":"44","author":"Silvestri","year":"2021","journal-title":"Drug Saf"},{"key":"2025072412172156200_llaf123-B45","first-page":"3469","article-title":"Decreased SUMOylation of the retinoblastoma protein in keratinocytes during the pathogenesis of vitiligo","volume":"18","author":"Zhou","year":"2018","journal-title":"Mol Med Rep"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf123\/62413467\/llaf123.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/8\/1598\/62413467\/llaf123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/8\/1598\/62413467\/llaf123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T16:17:33Z","timestamp":1753373853000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/8\/1598\/8078330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,3,14]]},"published-print":{"date-parts":[[2025,7,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf123","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,3,14]]}}}